Home Cart Sign in  
Chemical Structure| 110642-44-9 Chemical Structure| 110642-44-9

Structure of Epmedin C
CAS No.: 110642-44-9

Chemical Structure| 110642-44-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Epmedin C has an effect similar to estrogene and stimulation of osteoblasts. Epmedin C is a natural flavonoid extract from Epimedium sagittatum.

Synonyms: Baohuoside-VI

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Epmedin C

CAS No. :110642-44-9
Formula : C39H50O19
M.W : 822.80
SMILES Code : O[C@H]1[C@@H]([C@H](O[C@H]([C@@H]1O)OC2=CC(O)=C3C(C(O[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)C)O)O)O[C@@]5(O[C@H]([C@@H]([C@H]([C@H]5O)O)O)C)[H])=C(OC3=C2C/C=C(C)\C)C6=CC=C(C=C6)OC)=O)CO)O
Synonyms :
Baohuoside-VI
MDL No. :MFCD04039820
InChI Key :ULZLIYVOYYQJRO-JIYCBSMMSA-N
Pubchem ID :5748394

Safety of Epmedin C

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MC3T3-E1 cells 10, 20 μM 21 days Evaluate the effect of Epimedin C on mineralization nodule formation, results showed Epimedin C significantly alleviated DEX-induced inhibition of mineralization Front Pharmacol. 2022 Jul 4;13:894832
MC3T3-E1 cells 10, 20 μM 5 days Evaluate the effect of Epimedin C on alkaline phosphatase activity, results showed Epimedin C significantly alleviated DEX-induced inhibition of ALP activity Front Pharmacol. 2022 Jul 4;13:894832
MC3T3-E1 cells 1-60 μM 72 hours Evaluate the effect of Epimedin C on MC3T3-E1 cell viability, results showed no evident toxicity Front Pharmacol. 2022 Jul 4;13:894832
Mouse osteoblasts 10 μM 48 hours Epimedin C enhances migration and proliferation of osteoblasts after DXMS treatment Aging (Albany NY). 2023 Mar 14;15(6):2033-2045
mouse primary chondrocytes 10, 20 μM 24 hours To evaluate the protective effect of Epimedin C on IL-1β-induced chondrocyte damage, results showed that Epimedin C significantly improved cell viability, reduced apoptosis, and promoted cell proliferation Heliyon. 2024 Nov 15;10(23):e40458
human osteoarthritic chondrocytes 25 μM 72 hours To evaluate the anti-inflammatory and chondroprotective effects of Epimedin C, results showed that Epimedin C significantly increased the expression of collagenous and non-collagenous matrix proteins, demonstrating significant anabolic effects. Biomolecules. 2020 Jun 19;10(6):932

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Cisplatin-induced intestinal injury model Gavage 100, 200 mg/kg 10 consecutive days EFE alleviates cisplatin-induced intestinal injury by modulating oxidative stress, inflammation, and apoptosis Front Pharmacol. 2022 Oct 12;13:1040504
Kunming (KM) mice Type 2 diabetes mellitus (T2DM) mouse model Oral gavage 30 mg/kg Once daily for 28 days To evaluate the hypoglycemic effect and mechanism of Epmedin C in T2DM mice. Results showed that Epmedin C significantly reduced fasting blood glucose, HOMA-IR, and oral glucose tolerance, while increasing hepatic glycogen and insulin contents, improving oxidative stress and blood lipid levels. Nutrients. 2023 Dec 21;16(1):25
C57BL/6 mice Exercise endurance model Oral 10ug/kg Once daily for 10 days Epimedin C enhanced exercise endurance in mice, prolonging running time PLoS One. 2025 May 28;20(5):e0325031
C57BL/6J mice DMM-induced osteoarthritis model 20, 40 mg/kg 8 weeks To evaluate the therapeutic effect of Epimedin C on DMM-induced osteoarthritis, results showed that Epimedin C significantly preserved cartilage structure, activated Nrf2, and inhibited NLRP3 expression Heliyon. 2024 Nov 15;10(23):e40458
C57BL/6N mice Osteoporosis model Oral 1 × 10−3 μmol/mouse/day Once daily for 4 weeks Epimedin C protects against DXMS-induced osteoporosis via the NRF1/RhoA pathway Aging (Albany NY). 2023 Mar 14;15(6):2033-2045
Zebra fish larvae DEX-mediated bone impairment model Dissolved in culture water 10, 20 μM Evaluate the effect of Epimedin C on bone mineralization in zebra fish larvae, results showed Epimedin C significantly alleviated DEX-induced inhibition of bone mineralization Front Pharmacol. 2022 Jul 4;13:894832
Balb/c mice Epmedin C-induced liver injury model Intragastric administration 10 or 40 mg/kg Once daily for 4 weeks Successfully established the Epmedin C-induced liver injury mouse model, characterized by elevated serum aminotransferase levels, increased inflammatory cell infiltration, and vacuolar degeneration in the liver Chin Med. 2021 Sep 21;16(1):91

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.22mL

0.24mL

0.12mL

6.08mL

1.22mL

0.61mL

12.15mL

2.43mL

1.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories